help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2004-0066
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
90/3/1775    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Benvenuti, S.
Right arrow Articles by Peri, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benvenuti, S.
Right arrow Articles by Peri, A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ESTRADIOL
*TAMOXIFEN
Related Collections
Right arrow Neuroendocrinology and Pituitary
Right arrow Female Endocrinology
The Journal of Clinical Endocrinology & Metabolism Vol. 90, No. 3 1775-1782
Copyright © 2005 by The Endocrine Society

Estrogen and Selective Estrogen Receptor Modulators Exert Neuroprotective Effects and Stimulate the Expression of Selective Alzheimer’s Disease Indicator-1, a Recently Discovered Antiapoptotic Gene, in Human Neuroblast Long-Term Cell Cultures

Susanna Benvenuti, Paola Luciani, Gabriella Barbara Vannelli, Stefania Gelmini, Elisa Franceschi, Mario Serio and Alessandro Peri

Endocrine Unit (S.B., P.L., E.F., M.S., A.P.) and Clinical Biochemistry Unit (S.G.), Department of Clinical Physiopathology, Center for Research, Transfer and High Education on Chronic, Inflammatory, Degenerative, and Neoplastic Disorders, University of Florence; and Department of Anatomy, Histology, and Forensic Medicine (G.B.V.), University of Florence, 50139 Florence, Italy

Address all correspondence and requests for reprints to: Alessandro Peri, M.D., Ph.D., Endocrine Unit, Department of Clinical Physiopathology, University of Florence, Viale Pieraccini, 6, 50139 Florence, Italy. E-mail: a.peri{at}dfc.unifi.it.

According to the fact that Alzheimer’s disease (AD) is more common in postmenopausal women, estrogen treatment has been proposed. Experimental studies, still mostly performed using animal models, demonstrated that estrogen exerts neuroprotective effects. We previously established neuroblast long-term cell cultures from human fetal olfactory epithelium. In the present study, we addressed the role of estrogen in these unique human cells, which express both the estrogen receptor (ER)-{alpha} and ERß. We found that 17ß-estradiol (17ßE2) and the selective estrogen receptor modulators (SERMs) raloxifene and tamoxifen exerted neuroprotective effects, which were independent of cell proliferation, by increasing resistance against ß-amyloid-induced toxicity, with the exception of the highest concentrations of raloxifene (10 and 100 nM). In addition, 17ßE2 exposure protected from oxidative stress, reduced apoptosis, and increased the expression of the catalytic subunit of telomerase. Furthermore, we evaluated by quantitative real-time RT-PCR whether estrogen/SERMs modulate the expression of the recently discovered seladin-1 (selective AD indicator-1) gene, which exerts neuroprotective effects and is down-regulated in AD-vulnerable brain regions. 17ßE2 (100 pM to 100 nM) and SERMs (1 nM) significantly increased the amount of seladin-1 mRNA. Conversely, 10 and 100 nM raloxifene reduced the expression of seladin-1. The effect of estrogen appears mainly mediated by ER{alpha} because the selective ER{alpha} agonist propylpyrazole-triol determined a much greater increase of seladin-1 expression than the ERß agonist diarylpropionitrile. Our results add new evidence, using human neuronal cells, for a beneficial effect of estrogen in preventing neurodegenerative diseases and suggest for the first time that seladin-1 may mediate this effect.




This article has been cited by other articles:


Home page
J Mol EndocrinolHome page
A. Peri and M. Serio
Neuroprotective effects of the Alzheimer's disease-related gene seladin-1
J. Mol. Endocrinol., November 1, 2008; 41(5): 251 - 261.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
A. M. Etgen
Estrogens and Alzheimer's Disease: Is Cholesterol a Link?
Endocrinology, September 1, 2008; 149(9): 4253 - 4255.
[Full Text] [PDF]


Home page
J EndocrinolHome page
S Giannini, S Benvenuti, P Luciani, C Manuelli, I Cellai, C Deledda, A Pezzatini, G B Vannelli, E Maneschi, C M Rotella, et al.
Intermittent high glucose concentrations reduce neuronal precursor survival by altering the IGF system: the involvement of the neuroprotective factor DHCR24 (Seladin-1)
J. Endocrinol., September 1, 2008; 198(3): 523 - 532.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
P. Luciani, C. Deledda, F. Rosati, S. Benvenuti, I. Cellai, F. Dichiara, M. Morello, G. B. Vannelli, G. Danza, M. Serio, et al.
Seladin-1 Is a Fundamental Mediator of the Neuroprotective Effects of Estrogen in Human Neuroblast Long-Term Cell Cultures
Endocrinology, September 1, 2008; 149(9): 4256 - 4266.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
S. Tapia-Gonzalez, P. Carrero, O. Pernia, L. M Garcia-Segura, and Y. Diz-Chaves
Selective oestrogen receptor (ER) modulators reduce microglia reactivity in vivo after peripheral inflammation: potential role of microglial ERs
J. Endocrinol., July 1, 2008; 198(1): 219 - 230.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
S Benvenuti, P Luciani, I Cellai, C Deledda, S Baglioni, R Saccardi, S Urbani, F Francini, R Squecco, C Giuliani, et al.
Thyroid hormones promote cell differentiation and up-regulate the expression of the seladin-1 gene in in vitro models of human neuronal precursors
J. Endocrinol., May 1, 2008; 197(2): 437 - 446.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
K. Kuehnle, A. Crameri, R. E. Kalin, P. Luciani, S. Benvenuti, A. Peri, F. Ratti, M. Rodolfo, L. Kulic, F. L. Heppner, et al.
Prosurvival Effect of DHCR24/Seladin-1 in Acute and Chronic Responses to Oxidative Stress
Mol. Cell. Biol., January 15, 2008; 28(2): 539 - 550.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Luciani, S. Gelmini, E. Ferrante, A. Lania, S. Benvenuti, S. Baglioni, G. Mantovani, I. Cellai, F. Ammannati, A. Spada, et al.
Expression of the Antiapoptotic Gene Seladin-1 and Octreotide-Induced Apoptosis in Growth Hormone-Secreting and Nonfunctioning Pituitary Adenomas
J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6156 - 6161.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
O. Imamov, G.-J. Shim, M. Warner, and J.-A. Gustafsson
Estrogen Receptor beta in Health and Disease
Biol Reprod, November 1, 2005; 73(5): 866 - 871.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society